• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

20.01.2025
Investment Banks Are Ahead of Lenders

An advance guard of the U.S. banking segment has reported for the ending quarter of 2024 ahead of the corporate earnings season's major chapters, which are still coming in and are supposed to make an overall positive contribution. But what's interesting is, the variety of lending institutions performed a solid organic growth in terms of both revenue and pure income, while the essentially investment giants like Goldman Sachs (GS) and BlackRock (BLK) grew up on a much firmer foundation. There is an impression that well-organised asset management, based on proper contextual ad hoc and mid-term stock transactions, is still producing enhanced results when compared to the returns of somewhat shabby loan portfolios at still quite heavy interest rates.

A temporary increase in Blackrock market value was up to 6.5% at its highest intraday point on January 15, following its record ever $11.93 of equity per share (EPS) on an also absolutely highest number of $5.68 billion in quarterly sales. Blackrock's three-month achievements provided a 23.5% annual boost in EPS vs nearly14% expected at EPS of $11.06 per share, which was supposed in analyst pool projections in reputable news outlets like Bloomberg and Reuters. Many investment houses quickly adjusted their price target areas for Blackrock shares, while also keeping Outperform ratings on the stock. As an example, Keefe, Bruyette & Woods (KBW) revised its price goal for Blackrock to $1,180, citing the investment bank's diversified inflows and global expansion growth initiatives which made the company favorably positioning in the eyes of analysts and investors alike. Blackrock is currently traded around $1000 per share.

However, the Goldman Sachs (GS) effect even surpassed the previous case, with an emergence of totally new peaks above $625 on GS charts, where the shares of this widely recognized investment giant had never been before. The weekly gain was more than 11.5% from $560 per share at the closing price on January 10. Goldman Sachs provided last quarter's EPS at $11.95 per share, beating a $8.12 consensus forecast, with its revenue achieving as high as $13.87 billion vs $12.15 billion previously estimated on average. This means that GS net revenues are up 7% YoY but its adjusted income soared by 54%, so that the firm maintains its clear leadership in global investment banking, including merge and acquisition advisory and wealth management services. Such a strong kind of resilience revived inner projections for EPS of $47.50 for fiscal year 2025 and $52.50 for fiscal year 2026. Isn't this a ready-made reason for targets above $650, or even $700 per share in the coming months, or at least before the end of 2025? By the way, Goldman Sachs CEO David Solomon was freshly rewarded by an $80 million stock bonus to stay at the helm for another 5 years, and John Waldron, a chief operating officer who is seen by many as a successor to Solomon, who is 63 now, was also awarded with his retention bonus of the same $80 million in restricted stock. However, the huge crowd of Goldman Sachs investors on Wall Street is hardly feeling offended or sad either, given the stock's crazy growth pace by the banking segment's standards.

The very fact that a cycle of lower borrowing rates has started in 2024 on both sides of the pond is helping the banking environment tremendously, which may in turn expand into a real business so soon, but the process may be happening more slowly than many Wall Street inhabitants would like to see due to a pause in the dovish shift by the Federal Reserve and other financial regulators. Wells Fargo (WFC), which also has an increasingly advanced investment focus among its recovering lending business, gained more than 8% since last week's earnings' report, coming very close to all-time peaks around $78 per share. Shares of JPMorgan Chase (JPM) and Morgan Stanley (MS) also broke their previous price records, but gained within 5% and 7%, while the Bank of America (BAC) failed to add more than 2% for the reporting week, while its quarterly profits and sales were high but still within its previous lofty standards. The smaller part of investment business versus the credit component for the last three banks mentioned above seems like a reasonable justification for this tendency.

B
Buying More of Amazon

My personal feeling is that Amazon's quarterly report may have the ability to surprise investors from August 1st. During a recent background of massive correction moves in techs, shares of Amazon lost about 7.5% from 8th to 30th of July, compared to the e-commerce bellwether's peaking price above $200. This represented not such a big discount compared to many other components of the Nasdaq Composite index, pointing that the crowd wants to believe in Amazon's strength. Meanwhile, the impact of Microsoft's drop in the after-hours trading yesterday quickly increased this gap in Amazon price to 12% from all-time highs, which makes shares of Amazon much more attractive.

Analysts' consensus projections for a more than 10% surplus in Q2 sales to approach $150 billion are here, also betting for an EPS at least an inch above the psychological threshold of $1 per share, as it was last Christmas quarter's record achievement for the time being. However, could you imagine what would happen with a price if actual numbers come out far beyond consensus estimates? First, accelerating demand on cloud computing is a factor to drive Amazon Web Services (AWS) marginality up to the skies. The help of generative AI tailwinds is real. If so, forget about Amazon's core business, even though it is seemingly climbing to new highs as well. The retail platform and advertising income may benefit much from Amazon's faster deliveries, which may give more conversion, despite all those struggling low-end consumers. There was a big crowd of new loyalty program sign-ups on Prime Day. It generated $14 billion in sales in the US to mark nearly 11% of gains YoY, Adobe Analytics figured. This may boost overall record sales well above consensus ideas. I anticipate the sales number above $155 billion and EPS of $1.10 or even better.

That's why I decided to buy more Amazon shares, even without waiting for the official quarterly release. A break through $190 may give an extra boost to the stock's price immediately, but I don't want to buy above $200, when it currently trades between $175 and $180. Well, if something goes wrong, Amazon will come back soon. Yet, in my baseline scenario, the stock price would soar by double-digits, in after-hours this Thursday's night. Citigroup now has its target price for Amazon at $245 (!) per share, projecting a 17.5% surplus in AWS and operating income of $13.88 billion. This is surely not the main argument for my mind, but this certainly gives me extra power to stay positive on Amazon.

4085
A Chance to Add More to Stakes in Merck

Merck & Company quickly lost about 4% of its market value in the pre-market trading on July 30, to re-test its major $120 to $122.50 technical support area. This was an immediate response to the drug giant's updating its own earnings forecast for the rest of the year. Merck CEOs adjusted their guidance to a range between $7.94 and $8.04, from previous estimates of $8.53 to $8.65 per share. Yet, the main reasons for lower forecasts were seemingly boiling down to one-time charges from an acquisition of eye-focused drug developer EyeBio, which cost nearly $1.3 billion, or $0.51 per share. Consensus expectations at $8.16 per share included this factor into consideration, and so nothing extraordinary happened from our point of view.

Meanwhile, Merck business continued to win. Keytruda medicine for cancer immunotherapy, which used to make the largest revenue contribution, jumped above $30 billion annually, hitting $7.3 billion in the quarter, up 16% YoY vs expected numbers of slightly above $7.1 billion. Besides, Merck launched a drug Winrevair for a rare lung condition called pulmonary arterial hypertension. Many feel Winrevair may have a blockbuster potential, as it already gave $70 million in sales, which is higher than the most bullish estimates. Sales of Gardasil, a vaccine widely used in the prevention of human papillomavirus, were also growing. The company's boss Robert Davis separately emphasized Merck's participation in vaccine programs, including the US FDA regulatory approval and CDC's (The Centers for Disease Control and Prevention) recommendation for a pneumococcal vaccine, and positive results from a trial of an investigational RSV (respiratory syncytial virus) preventative monoclonal antibody for infants.

From a pure financial point of view, the company raised its full-year 2024 sales projections to a slightly higher range of $63.4 billion to $64.4 billion. Merck's sales globally rose by 7% to $16.1 billion, above average expectations of $15.8 billion, sales added 11% if the Wall Street crowd takes into account adjusting for currency exchange impacts. On Tuesday Merck also revealed $5.5 billion of Q2 profit, or $2.14 per share. Excluding this one-time stuff, the last quarter brought $2.28 per share vs consensus expectations of $2.15. The outlook looks so strong, that any current price discount is just an opportunity to add more to investors' stake in Merck. Merck is surely a top pick, even though not a buy for immediate use, better to postpone for a week or so until the dust settles.

3859
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
APE Stuck in a Flat Range

ApeCoin (APE) is experiencing a rise of 4.7% this week, reaching $0.796. This increase has allowed the token to break through the resistance of the downside trend that has persisted since March 13. However, the current price movements are primarily within a flat range, indicating that APE is struggling to gain further upward momentum.

A potential catalyst for future growth is the ApeCoin DAO's proposal to create a Bored Ape-themed hotel in Bangkok, which is garnering significant support from the community. If the project proceeds, it could positively impact the token's value. With this development, APE has the potential to test the resistance level at $1.000.

3921
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Western Union Is Going for a Rebound

After a decline from April through June, with prices dipping by 12.7% to $12.16 per share, Western Union (WU) stocks have started to rebound, reaching $12.83 by the end of July. They have also charted a Head and Shoulders pattern, indicating potential upside.

Weak financial performance in Q2 2024 has already been priced in, with Wall Street expecting Q2 EPS to drop by 13.7% YoY and revenues to tumble by 9.4% YoY. This suggests that the stock is unlikely to decline further. If WU's financial performance meets or exceeds consensus expectations, prices could continue to rise in August.

There is a 16.5% upside potential, targeting $14.00-15.00 per share, with a secure stop loss placed at $10.70.

3776
146

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors